Updates in PsO Sequencing and Future Research

As the psoriasis (PsO) armamentarium has grown, the question of how to sequence therapies — both initially and following partial or inadequate response — has become increasingly consequential. A patient's response to an IL-23 directed therapy, whether injectable or oral, provides direct in vivo information about the contribution of the IL-23 pathway to their individual disease. Partial response — on the order of 50% to 60% skin improvement after an adequate trial of at least 3 months — indicates that IL-23 inhibition is producing meaningful benefit and supports escalation within the class to a more potent IL-23 monoclonal antibody. Absence of meaningful response after an adequate trial argues against remaining within the IL-23 class and supports a mechanism switch to an IL-17 inhibitor rather than substituting one IL-23 directed agent for another. This sequencing logic provides a more principled basis for sequential prescribing than trial-and-error substitution and is directly applicable whether the initial IL-23 directed therapy was injectable or oral. Clinicians should also account for the time course of IL-23 inhibition: these agents typically reach maximal effect beyond week 16, often requiring 24 to 36 weeks for full benefit, and patients and clinicians must align expectations accordingly to avoid premature switching based on an incomplete response assessment.

Several important clinical questions in PsO remain incompletely answered and are likely to shape the field's trajectory over the next several years. Whether early, aggressive treatment with biologic therapy — initiated before structural joint damage or significant comorbid disease burden has accumulated — improves long-term outcomes for both skin and musculoskeletal disease is an active area of investigation with direct implications for when clinicians should escalate from conventional to advanced therapy. The relationship between biologic treatment and cardiovascular risk represents a second major frontier: PsO is associated with elevated cardiovascular risk through shared inflammatory mechanisms, and the degree to which effective suppression of psoriatic inflammation modifies that risk over time remains incompletely characterized but is an area of growing evidence. Body weight intersects with both questions — lower body weight is associated with better biologic response rates and with improved cardiovascular outcomes in PsO patients — and understanding how weight modulates both efficacy and downstream health outcomes has meaningful implications for how clinicians counsel patients about lifestyle alongside pharmacologic management.

In this HCPLive Special Report final segment, Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine, surveys the therapeutic developments most likely to alter practice patterns over the next 5 years. Biologics with substantially extended half-lives capable of supporting dosing intervals of every 6 to 12 months — rather than the current standard of every 8 to 12 weeks at maintenance — are in development and would fundamentally change the treatment experience for patients who are well-controlled but find even quarterly injections burdensome.

Next‑generation oral agents continue to progress through clinical development, contributing additional options to the psoriasis treatment landscape, though their ultimate role relative to injectable biologics remains to be defined. While some have shown promising efficacy signals and acceptable safety profiles in controlled trial settings, these agents have not yet demonstrated the consistency, durability, or depth of response that underpin long‑term confidence in established biologic therapies. As a result, competition with injectable biologics is likely to remain selective and patient‑specific rather than broadly transformative.

Strober suggests that the distinction between oral and injectable therapy may evolve over time, but injectable biologics continue to represent the standard for patients with more significant disease burden, particularly where sustained clearance and long‑term outcomes are key priorities. Effectively navigating this landscape requires clinicians to balance short‑term efficacy signals with mechanistic rationale, durability of evidence, comorbidity considerations, and patient expectations—recognizing that psoriasis management is fundamentally longitudinal and that early convenience advantages must be weighed against long‑term disease control in a lifelong condition.